MARTINDALE PHARMA
Making lives better

Building A2
Glory Park
Wooburn Green
High Wycombe
HP10 0DF
United Kingdom

t +44 (0) 1628 551900
f +44 (0) 1628 529848
e connect@martindalepharma.co.uk
w martindalepharma.co.uk

Date

Direct Communication to patient, carers and community workers who have been supplied with Prenoxad Injection

Information regarding correcting the historic error on Prenoxad labelling.

You have been provided with Prenoxad Injection as Take Home Naloxone. We have made some changes to the labelling of Prenoxad Injection. The labelling now shows the strength as 0.91mg/mL rather than 1mg/mL.

Please note that there is no difference in the amount of active ingredient (naloxone hydrochloride) in the product. The change is in the way the drug product strength is presented on the product labelling.

As there is **no change** in the product formulation there are no implications as regards the clinical effect or in **how the product is used**.

Please use the product as directed by your service provider, case worker or doctor.

Call for reporting:
As a reminder, there is a need to report any suspected adverse reactions to the MHRA via the Yellow Card Scheme Website: http://www.mhra.gov.uk/yellowcard.
Pharmacovigilance department in Aurum Pharmaceuticals Ltd (an entity of Martindale Pharma):
Email: drugsafety@pharsafer.com

If you require any further clarification or have any questions, please contact Martindale Pharma Medical Information at medinfo@martindalepharma.co.uk.